MLTX — MoonLake Immunotherapeutics Share News
0.000.00%
Last trade - 00:00Swiss stocks - Factors to watch on May 13
MoonLake Immunotherapeutics reports results for the quarter ended March 31 - Earnings Summary
Brief: Moonlake Secures Up To $500 Million In Non-Dilutive Financing From Hercules Capital And Announces A Capital Markets Update On April 29 To Provide Important Clinical Updates
MoonLake Immunotherapeutics reports results for the quarter ended December 31 - Earnings Summary
Brief: Moonlake Initiates Three New Clinical Trials And Expands Portfolio Of Indications For The Nanobody Sonelokimab
Brief: Moonlake Immunotherapeutics Topline Primary Endpoint Readout At Week 16 For Phase 3 IZAR Program Expected In H1 2026
Brief: Moonlake Immunotherapeutics Reports Q3 2024 Financial Results And Provides A Business Update
MoonLake Immunotherapeutics reports results for the quarter ended in June - Earnings Summary
MoonLake Immunotherapeutics expected to post a loss of 28 cents a share - Earnings Preview
Brief: Moonlake Immunotherapeutics Announces Positive Regulatory Feedback From Both FDA And EMA On Path For The Phase 3 Program For The Nanobody® Sonelokimab In Psoriatic Arthritis
Brief: MoonLake Immunotherapeutics starts Phase 3 VELA program of the Nanobody sonelokimab in patients with moderate-to-severe hidradenitis suppurativa
MoonLake Immunotherapeutics expected to post a loss of 27 cents a share - Earnings Preview
Brief: MoonLake Immunotherapeutics Announces Positive Feedback from both FDA and EMA on Regulatory Path for the Phase 3 Program of the Nanobody® sonelokimab (SLK) in Hidradenitis Suppurativa (HS)
Swiss stocks - Factors to watch on November 14
U.S. STOCKS ON THE MOVE-Paramount Global, Bumble, Booking Holdings
MoonLake tumbles after psoriatic arthritis trial data
Brief: Moonlake Immunotherapeutics Announces The Full Dataset From Its 24-Week MIRA Clinical Trial
Brief: Moonlake Immunotherapeutic to Present Phase 2 Mira Primary Analysis Trial Results With Nanobody® Sonelokimab In Hidradenitis Suppurativa At The European Academy Of Dermatology And Venereology Congress
U.S. STOCKS ON THE MOVE-First Solar, Canadian Solar